首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1422702

血液篩檢市場- 副產品（試劑和試劑盒[NAT、ELISA]、儀器）、技術（血清學/免疫測定、快速測試、蛋白質印跡測定、NGS）、最終用途（醫院、血庫、病理實驗室） -全球預測, 2024-2032

Blood Screening Market - By Product (Reagents & Kits [NAT, ELISA], Instruments), Technology (Serology/Immunoassays, Rapid Test, Western Blot Assays, NGS), End-use (Hospitals, Blood Banks, Pathology Laboratories) - Global Forecast, 2024-2032

出版日期: 2023年12月07日 | 出版商:

Global Market Insights Inc. | 英文 280 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於醫療保健技術的進步以及人們對早期疾病檢測重要性的認知不斷提高，血液篩檢市場預計在 2024 年至 2032 年間複合CAGR為 7.3%。血液篩檢有助於識別各種醫療狀況，包括傳染病和遺傳性疾病。根據世界衛生組織的數據，2022 年共有 130 萬人死於結核病，使其成為僅次於 COVID-19 的全球第二大傳染病。

控制和預防傳染病爆發的持續努力導致人們更加關注血液篩檢，將其作為公共衛生措施的重要組成部分。此外，血庫和輸血中心進行血液篩檢以確保捐血安全的需求進一步刺激了市場成長。

血液篩檢產業根據產品、技術、最終用途和地區進行細分。

由於檢測血液樣本中特定蛋白質的精確度和多功能性，蛋白質印跡分析領域預計將在 2024 年至 2032 年期間顯著成長。該技術具有很高的靈敏度和準確性，使其在識別與傳染病或其他醫療狀況相關的各種抗體、抗原或特定蛋白質方面特別有效。它提供了有關血液樣本中目標分子的存在和濃度的詳細資訊，使其成為診斷和監測愛滋病毒和某些類型癌症等疾病的寶貴工具。

病理實驗室部門預計在預測期內產生可觀的收入，這得益於進行全面和精確診斷測試的專業知識。這些實驗室擁有專業設備和熟練的專業人員，確保了血液篩檢結果的準確性和可靠性。此外，預防保健和常規健康檢查的日益成長趨勢增加了對病理實驗室提供的血液篩檢服務的需求。

受該地區不斷成長的人口的青睞，亞太地區血液篩檢產業規模預計將在 2024 年至 2032 年期間大幅成長。對加強醫療基礎設施和採用先進醫療技術的承諾有助於在預防性醫療實踐中更廣泛地使用血液篩檢。隨著政府和醫療保健提供者越來越關注應對公共衛生挑戰，亞太地區的血液篩檢市場經歷了強勁成長。

產業生態系統分析
產業影響力
- 成長動力
  - 傳染病流行率不斷上升
  - 血液篩檢技術的進步
  - 不斷增加的輸血程序
- 產業陷阱與挑戰
  - 先進技術成本高
  - 獲得訓練有素的專業人員的機會有限
成長潛力分析
監管環境
未來市場趨勢
技術景觀
定價分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：血液篩檢市場規模及預測：依產品分類，2018-2032 年

主要動向：按產品
試劑和試劑盒
- NAT 試劑和試劑盒
  - 酶和聚合酶
  - 標準和控制
  - 探針和引子
  - 緩衝液、核苷酸和溶液
  - 標記和檢測試劑
- 酵素連結免疫吸附試驗
  - 免疫吸附劑
  - 控制
  - 共軛物
  - 基材
  - 樣品稀釋液和清洗液
- 其他試劑和試劑盒
儀器

第 6 章：血液篩檢市場規模與預測：按技術分類，2018-2032 年

主要動力向：靠技術
核酸檢測
- 轉錄介導的擴增
- 即時定量PCR
血清學/免疫測定
- 化學發光免疫分析
- 螢光免疫分析
- 比色計免疫分析/ELISA
快速測試
蛋白質印跡分析
下一代定序

第 7 章：血液篩檢市場規模與預測：依最終用途，2018-2032 年

主要動向：依最終用途
醫院
血庫
病理實驗室

第 8 章：血液篩檢市場規模及預測：按地區分類，2018-2032 年

主要動向：按地區
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Grifols, S.A.
Hologic, Inc.
QIAGEN N.V.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Siemens Healthineers AG
Thermo Fisher Scientific, Inc.
SOFINA s.a (Biomerieux)
Danaher Corporation
Ortho-Clinical Diagnostics, Inc.
DiaSorin S.p.A.

簡介目錄

Product Code: 7618

Blood Screening Market is anticipated to register a CAGR of 7.3% between 2024 and 2032, owing to the advancements in healthcare technologies and increased awareness regarding the importance of early disease detection. Blood screening helps in identifying various medical conditions, including infectious diseases and genetic disorders. As per WHO, a total of 1.3 million people died from tuberculosis in 2022, making it the second leading infectious disease worldwide after COVID-19.

The ongoing efforts to control and prevent infectious outbreaks have led to an increased focus on blood screening as a vital component of public health initiatives. Additionally, the need for blood screening in blood banks and transfusion centers to ensure the safety of blood donations further stimulates market growth.

Blood screening industry is segmented based on product, technology, end-use, and region.

Western blot assay segment is slated to witness significant growth during 2024-2032, owing to the precision and versatility in detecting specific proteins within blood samples. This technique offers high sensitivity and accuracy, making it particularly effective in identifying various antibodies, antigens, or specific proteins associated with infectious diseases or other medical conditions. It provides detailed information about the presence and concentration of target molecules in a blood sample, making it an invaluable tool in the diagnosis and monitoring of diseases such as HIV and certain types of cancers.

Pathology laboratories segment is poised to generate notable revenues over the forecast period, favored by the expertise in conducting comprehensive and precise diagnostic tests. The accessibility of specialized equipment and skilled professionals in these laboratories ensures the accuracy and reliability of blood screening results. Additionally, the increasing trend toward preventive healthcare and routine health check-ups enhances the demand for blood screening services provided by pathology laboratories.

Asia Pacific blood screening industry size is anticipated to grow at a significant pace over 2024-2032, favored by the region's growing population. The commitment towards enhancing healthcare infrastructure and the adoption of advanced medical technologies contribute to the wider usage of blood screening in preventive healthcare practices. As governments and healthcare providers increasingly focus on addressing public health challenges, the blood screening market experiences robust growth in APAC.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & working
1.3 Data collection
1.4 Forecast calculations
1.5 Data validation
1.6 Data Sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global blood screening market 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Product trends
- 2.1.4 Technology trends
- 2.1.5 End-use trends

Chapter 3 Blood Screening Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of infectious diseases
  - 3.2.1.2 Advancements in blood screening technology
  - 3.2.1.3 Growing blood transfusion procedures
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost of advanced technologies
  - 3.2.2.2 Limited access to trained professionals
3.3 Growth potential analysis
- 3.3.1 By product
- 3.3.2 By technology
- 3.3.3 By end-use
3.4 Regulatory landscape
3.5 Future market trends
3.6 Technological landscape
3.7 Pricing analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis, 2023
4.3 Company market share analysis, 2023
4.4 Competitive analysis of major market players, 2023
4.5 Competitive positioning matrix, 2023
4.6 Strategy dashboard, 2023

Chapter 5 Blood Screening Market Size and Forecast, By Product, 2018-2032 (USD Million)

5.1 Key trends, by product
5.2 Reagents & kits
- 5.2.1 NAT reagents & kits
  - 5.2.1.1 Enzymes & polymerases
  - 5.2.1.2 Standards & controls
  - 5.2.1.3 Probes & primers
  - 5.2.1.4 Buffer, nucleotides, and solutions
  - 5.2.1.5 Labelling & detection reagents
- 5.2.2 ELISA
  - 5.2.2.1 Immunosorbents
  - 5.2.2.2 Controls
  - 5.2.2.3 Conjugates
  - 5.2.2.4 Substrates
  - 5.2.2.5 Sample diluents & wash solutions
- 5.2.3 Other reagents & kits
5.3 Instruments

Chapter 6 Blood Screening Market Size and Forecast, By Technology, 2018-2032 (USD Million)

6.1 Key trends, by technology
6.2 Nucleic acid test
- 6.2.1 Transcription-mediated amplification
- 6.2.2 Real-time PCR
6.3 Serology/immunoassays
- 6.3.1 Chemiluminescence immunoassay
- 6.3.2 Fluoresecent immunoassays
- 6.3.3 Colorimeter immunoassays/ELISA
6.4 Rapid test
6.5 Western blot assays
6.6 Next generation sequencing

Chapter 7 Blood Screening Market Size and Forecast, By End-use, 2018-2032 (USD Million)

7.1 Key trends, by end-use
7.2 Hospitals
7.3 Blood banks
7.4 Pathology laboratories

Chapter 8 Blood Screening Market Size and Forecast, By Region, 2018-2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East & Africa